Background Dual blockade of both EGFR and VEGFR pathways in EGFR‐mutant NSCLC
have shown enhanced antitumor efficacy versus EGFR‐TKIs alone. Apatinib is an orally …

Background Blocking vascular endothelial growth factor receptor (VEGFR) pathway can
enhance the efficacy of EGFR-TKI in EGFRm NSCLC. ACTIVE is the first phase III study …

Background Gefitinib, as the first epidermal growth factor receptor tyrosine kinase inhibitors
(EGFR-TKI) approved for the treatment of advanced non-small cell lung cancer (NSCLC) …

Introduction Blocking vascular endothelial growth factor pathway can enhance the efficacy of
EGFR tyrosine kinase inhibitors in EGFR-mutant NSCLC. ACTIVE is the first phase 3 study …

Background This phase I trial was primarily conducted to determine the maximum tolerated
dose (MTD) of apatinib combined with docetaxel in advanced lung adenocarcinoma patients …

Background Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs)-
rechallenged therapy for EGFR-mutant non-small cell lung cancer (NSCLC) patients who …

In the absence of a driver mutation, chemotherapy is the standard treatment option as first-
and second-line therapy for advanced non-small-cell lung cancer (NSCLC). Though a large …

Background This trial aimed to investigate the treatment response, survival profiles and
treatment-related adverse events (AEs) of apatinib plus docetaxel in advanced non …

Background: Apatinib is a tyrosine kinase inhibitor (TKI) that selectively inhibits the vascular
endothelial growth factor receptor-2. A weighted pooled analysis was performed to evaluate …

Chemotherapy is the standard treatment of in advanced lung adenocarcinoma patients
without driver mutation. However, few drugs could be selected when diseases progressed …